ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion
Open Access
- 8 February 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (22) , e19836
Abstract
Immune checkpoint blockade (ICB) efficacy is limited by tumor‐intrinsic immune escape mechanisms. This study identifies the transcription factor ZBTB21 as a central orchestrator of dual immunosuppressive programs. ZBTB21 epigenetically silences gasdermin D (GSDMD)‐dependent pyroptosis by restricting STAT1‐mediated chromatin accessibility via H3K27ac modulation at the GSDMD locus. Simultaneously, it represses MHC‐I antigen presentation by attenuating IRF1 expression and its transactivation capacity. Genetic ablation of ZBTB21 unleashes pyroptotic cell death and enhances tumor antigen presentation, establishing a self‐reinforcing cycle that recruits and activates CD8 + T cells. This dual activation overcomes ICB resistance in murine models, while B2M deletion ablates efficacy, confirming MHC‐I dependency. Pharmacological inhibition of ZBTB21 with dobutamine disrupts its DNA‐binding domain, which triggers pyroptotic inflammation and MHC‐I upregulation to synergize with anti‐PD‐1 therapy. Thus, ZBTB21 represents a druggable nexus coordinating pyroptosis resistance and antigen presentation escape, providing a combinatorial strategy to reinvigorate antitumor immunity.Keywords
Funding Information
- National Natural Science Foundation of China (81672292)
- National Natural Science Foundation of China (82472814)
- China Postdoctoral Science Foundation (2025M782124)
- Natural Science Foundation of Shandong Province (ZR2021LSW006)
- Natural Science Foundation of Shandong Province (ZR2024QH274)
This publication has 44 references indexed in Scilit:
- TCellSI: A novel method for T cell state assessment and its applications in immune environment predictioniMeta, 2024
- The cancer-immunity cycle: Indication, genotype, and immunotypeImmunity, 2023
- CD8+ T cells in the cancer-immunity cycleImmunity, 2023
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell, 2021
- Cancer Epigenetics, Tumor Immunity, and ImmunotherapyTrends in Cancer, 2020
- Inflammasome-activated gasdermin D causes pyroptosis by forming membrane poresNature, 2016
- PyroptosisCurrent Biology, 2016
- From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathwayDrug Discovery Today, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013